HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

J R McGhee Selected Research

Peptides (Polypeptides)

7/2001Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis.
4/2000Comparison of nasal and oral tolerance for the prevention of collagen induced murine arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


J R McGhee Research Topics

Disease

4Human Influenza (Influenza)
10/2001 - 03/2000
4Infections
10/2000 - 06/2000
3Colitis
09/2001 - 09/2000
2Hypersensitivity (Allergy)
07/2001 - 03/2001
2Inflammation (Inflammations)
04/2001 - 02/2000
1Vaginitis
11/2001
1Pneumonia (Pneumonitis)
10/2001
1Ulcer
09/2001
1Autoimmune Diseases (Autoimmune Disease)
07/2001
1Encephalomyelitis (Myeloencephalitis)
07/2001
1Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
07/2001
1Multiple Sclerosis
07/2001
1Cystic Fibrosis (Mucoviscidosis)
05/2001
1Dental Caries (Decay, Dental)
03/2001
1Hemolytic-Uremic Syndrome
02/2001
1Virus Diseases (Viral Diseases)
01/2001
1Cholera
10/2000
1Diarrhea
10/2000
1Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
09/2000
1Fibrosis (Cirrhosis)
09/2000
1Acute-Phase Reaction
07/2000
1Rotavirus Infections
06/2000
1Reinfection
06/2000
1Experimental Arthritis
04/2000
1Arthritis (Polyarthritis)
04/2000
1Emerging Communicable Diseases (Emerging Infectious Diseases)
03/2000
1Nasal Polyps (Nasal Polyp)
02/2000

Drug/Important Bio-Agent (IBA)

3CytokinesIBA
10/2001 - 09/2000
3Cholera ToxinIBA
10/2001 - 10/2000
3HaptensIBA
09/2001 - 09/2000
3Immunoglobulin E (IgE)IBA
04/2001 - 02/2000
3VaccinesIBA
03/2001 - 03/2000
3AntibodiesIBA
02/2001 - 10/2000
2Proteins (Proteins, Gene)FDA Link
09/2001 - 07/2001
2Sulfonic AcidsIBA
09/2001 - 09/2000
2Peptides (Polypeptides)IBA
07/2001 - 04/2000
2Immunoglobulin A (IgA)IBA
04/2001 - 06/2000
2Immunoglobulin G (IgG)IBA
10/2000 - 06/2000
2Interleukin-6 (Interleukin 6)IBA
07/2000 - 06/2000
2Interferon-gamma (Interferon, gamma)IBA
06/2000 - 06/2000
1gamma-delta T-Cell Antigen Receptors (T-Cell Receptor delta-Chain)IBA
11/2001
1Messenger RNA (mRNA)IBA
10/2001
1Chemokine CCL4IBA
10/2001
1Lymphotoxin beta ReceptorIBA
09/2001
1AutoantigensIBA
07/2001
1Culture MediaIBA
07/2001
1T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA
07/2001
1Complementary DNA (cDNA)IBA
05/2001
1LipidsIBA
05/2001
1DNA (Deoxyribonucleic Acid)IBA
05/2001
1Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA
05/2001
1Shiga Toxins (Vero Toxin)IBA
02/2001
1Neutralizing AntibodiesIBA
02/2001
1Acute-Phase Proteins (Acute-Phase Protein)IBA
10/2000
1Cholera VaccinesFDA Link
10/2000
1C-Reactive ProteinIBA
10/2000
1Enterotoxins (Enterotoxin)IBA
10/2000
1InterferonsIBA
09/2000
1InterleukinsIBA
09/2000
1Interleukin-4 (Interleukin 4)IBA
09/2000
1Interleukin-12 (IL 12)IBA
09/2000
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
07/2000
1Hormones (Hormone)IBA
07/2000
1CollagenIBA
04/2000
1Collagen Type II (Type II Collagen)IBA
04/2000
1Viral VaccinesIBA
03/2000
1Rotavirus VaccinesIBA
03/2000
1Indicators and Reagents (Reagents)IBA
02/2000
1Syntaxin 1IBA
02/2000

Therapy/Procedure

1Mucosal Administration
07/2001
1Intranasal Administration
03/2001